)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Enovis
Enovis (ENOV) investor relations material
Enovis Wells Fargo 21st Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Wells Fargo 21st Annual Healthcare Conference summary8 Sep, 2026
Market overview and growth outlook
U.S. ortho market has returned to pre-COVID seasonality, with summer slowdowns and recent strong performance.
European markets are slowing, but share gains and above-market growth continue.
No significant impact from ACA or government budget shifts observed; strikes and policy decisions in Europe noted but not materially affecting results.
Recon expected to grow mid to high single digits, P&R mid single digits; long-term growth supported by aging population and procedural demand.
Acquisition and technology integration
Acquisition of eCential aims to strengthen position in shoulder robotics and accelerate knee market entry.
Integrated system will combine AI-powered planning/navigation with robotic assistance, targeting both hospitals and ASCs.
U.S. knee robot launch planned for 2028; integration milestones to be outlined after deal closes, expected in Q4.
Regulatory pathway considered well-understood due to eCential's proven technology and team.
Financial targets and capital allocation
Top-line growth guidance for Recon and P&R maintained; acquisition seen as a growth unlock and free cash flow driver.
EBITDA margin to decline by 100 bps next year due to investment, with underlying improvement of 50 bps; margin expansion resumes in 2028.
Free cash flow conversion targeted at 50% next year, progressing to 70%+ by 2029; $100M cash generation expected next year.
Debt ratio to temporarily rise to 3.5x, then return to 3.1x; cash and revolver to fund acquisition.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Enovis
- Acquisition of a surgical robotics leader for €176M plus milestones to boost innovation and growth.ENOV
M&A announcement - Q2 2026 saw 5% organic growth, margin gains, strong cash flow, and reaffirmed guidance.ENOVQ2 2026
- Double-digit growth, tech innovation, and ASC expansion drive strong outlook for 2026.ENOV2026 CG Musculoskeletal Conference
- All director nominees and proposals were approved by majority, with no stakeholder questions.ENOVAGM 2026
- Q1 2026 sales up 5%, margins and EPS improved, guidance reaffirmed amid macro headwinds.ENOVQ1 2026
- Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.ENOVProxy filing
- Board recommends all proposals, emphasizing governance, pay-for-performance, and ESG focus.ENOVProxy filing
- Q1 2025 sales up 8% with margin gains; revenue outlook raised, EBITDA trimmed on tariffs.ENOVQ1 2025
- 6%-6.5% organic growth and margin expansion expected in 2025, driven by innovation and integration.ENOV43rd Annual J.P. Morgan Healthcare Conference 2025
Next Enovis earnings date
Q3 20265 Nov, 2026
Enovis
Next Enovis earnings date
Q3 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Enovis Corporation is a medical technology company focused on developing innovative solutions for orthopedics and rehabilitation. The company designs, manufactures, and distributes medical devices, including braces, prosthetics, joint replacement implants, and rehabilitation equipment. Enovis serves healthcare providers, hospitals, and patients, offering products that support mobility, injury recovery, and surgical procedures. Enovis Corporation is headquartered in Wilmington, Delaware, and its shares are listed on the NYSE.